Risedronate Sodium Tablet, Film Coated
Product Images NDC 59762-0406

9 FDA label images from Mylan Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 59762-0406). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Chemical Structure Of Risedronate Sodium Hemi-pentahydrate Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Risedronate Sodium For Oral Administration Contains The Equivalent Of 5, 30, 35, 75, Or 150 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. (Risedronate Sodium Tabs 35 mg 150 mg 01)

The Chemical Structure Of Risedronate Sodium Hemi-pentahydrate Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Risedronate Sodium For Oral Administration Contains The Equivalent Of 5, 30, 35, 75, Or 150 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. (Risedronate Sodium Tabs 35 mg   150 mg 01)
Chemical structure of Risedronate Sodium, depicted with its molecular components including phosphate groups, a pyridine ring, and water of hydration (2.5 H2O).*
FDA Label Image

Figure 1 (Risedronate Sodium Tabs 35 mg 150 mg 02)

Figure 1 (Risedronate Sodium Tabs 35 mg   150 mg 02)
Bar chart titled 'Nonvertebral Osteoporosis-Related Fractures Cumulative Incidence Over 3 Years Combined VERT MN and VERT NA' comparing the percentage of patients experiencing fractures at different sites (All, Wrist, Humerus, Hip, Pelvis, Leg, Clavicle) between placebo and 5 mg Risedronate Sodium groups. The chart shows lower fracture incidence in the Risedronate Sodium group for most fracture sites compared to placebo.*
FDA Label Image

Figure 2 (Risedronate Sodium Tabs 35 mg 150 mg 03)

Figure 2 (Risedronate Sodium Tabs 35 mg   150 mg 03)
A bar chart titled 'Change in BMD from Baseline 2-Year Prevention Study' comparing mean percent change in bone mineral density (BMD) ± standard error at three sites: lumbar spine, femoral neck, and femoral trochanter. It shows data for placebo versus Risedronate Sodium 5 mg, with sample sizes noted for each group. Risedronate Sodium groups show positive changes in BMD at all sites, while placebo groups show negative changes.*
FDA Label Image

Figure 3 (Risedronate Sodium Tabs 35 mg 150 mg 04)

Figure 3 (Risedronate Sodium Tabs 35 mg   150 mg 04)
A bar chart titled 'Change in BMD from Baseline Patients Recently Initiating Glucocorticoid Therapy' comparing placebo and Risedronate Sodium 5 mg effects on bone mineral density (BMD) mean percent change ± SE. Data is shown for lumbar spine, femoral neck, and femoral trochanter with sample sizes noted for each group.*
FDA Label Image

Figure 4 (Risedronate Sodium Tabs 35 mg 150 mg 05)

Figure 4 (Risedronate Sodium Tabs 35 mg   150 mg 05)
A bar graph titled 'Figure 4 Change in BMD from Baseline Patients on Long-Term Glucocorticoid Therapy' comparing bone mineral density (BMD) percentage change for placebo and Risedronate Sodium 5 mg groups at three anatomical sites: Lumbar Spine, Femoral Neck, and Femoral Trochanter. The graph shows mean percentage changes with standard error bars and sample sizes (n) for each group and site.*
FDA Label Image

Figure 5 (Risedronate Sodium Tabs 35 mg 150 mg 06)

Figure 5 (Risedronate Sodium Tabs 35 mg   150 mg 06)
A bar chart comparing the incidence (%) of vertebral fractures in patients either continuing or initiating glucocorticoid therapy, with groups treated by placebo versus Risedronate Sodium 5 mg. The chart shows lower fracture incidence for patients treated with Risedronate Sodium across all categories: continuing treatment, initiating treatment, and combined groups. Sample sizes (n) per group are displayed above each bar.*
FDA Label Image

Figure 6 (Risedronate Sodium Tabs 35 mg 150 mg 07)

Figure 6 (Risedronate Sodium Tabs 35 mg   150 mg 07)
A line graph titled 'Mean Percent Change from Baseline in Serum Alkaline Phosphatase Excess by Visit' showing percentage change on the Y-axis against visit days on the X-axis up to 600 days. Data are compared between DIDRONEL 400 mg (dashed line) and Risedronate Sodium 30 mg (solid line) treatments, including segments for treatment, follow-up, and extended follow-up periods with standard error bars and sample sizes noted at several points.*
FDA Label Image

Principal Display Panelndc 59762-0405-4dispense The Enclosed Medication Guide To Each Patientgreenstone® Brand4 Week Supply (4 Tablets) Once-a-week 4 Tabletsrisedronate Sodium Tablets35 mgrx Only (Risedronate Sodium Tabs 35 mg 150 mg 08)

Principal Display Panelndc 59762-0405-4dispense The Enclosed Medication Guide To Each Patientgreenstone® Brand4 Week Supply (4 Tablets) Once-a-week 4 Tabletsrisedronate Sodium Tablets35 mgrx Only (Risedronate Sodium Tabs 35 mg   150 mg 08)
Risedronate Sodium 35 mg film-coated tablets packaging label by Mylan Pharmaceuticals, Inc. The label features the GREENSTONE Brand name, indicates a 4-week supply of 4 tablets (once-a-week dosing), and includes the NDC 59762-0405-4. The label states 'Dispense the enclosed Medication Guide to each patient' and specifies Rx only.*
FDA Label Image

Principal Display Panelndc 59762-0406-1dispense The Enclosed Medication Guide To Each Patientgreenstone® Brandone Month Pack (1 Tablet) Once-a-month 1 Tabletrisedronate Sodium Tablets150 mgrx Only (Risedronate Sodium Tabs 35 mg 150 mg 09)

Principal Display Panelndc 59762-0406-1dispense The Enclosed Medication Guide To Each Patientgreenstone® Brandone Month Pack (1 Tablet) Once-a-month 1 Tabletrisedronate Sodium Tablets150 mgrx Only (Risedronate Sodium Tabs 35 mg   150 mg 09)
Packaging label for Risedronate Sodium tablets, 150 mg strength, film-coated. The label indicates it is a prescription drug (Rx only) and is a one-month pack containing one tablet for once-a-month oral administration. The product is branded as GREENSTONE® and distributed by Mylan Pharmaceuticals, Inc. The label includes the NDC 59762-0406-1 and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.